To better study and monitor diverse populations, leaders in science and healthcare choose the Mitra® microsampler, a specimen collection device that is a user-friendly alternative to venipuncture blood draws. Organizations prefer the Mitra® devices with VAMS® precise microsampling technology — a convenient alternative to traditional, clinic-based sample collection. Mitra devices offer greater comfort and precision during sample collection, eliminating the challenges recruitment and compliance during clinical research studies and therapeutic drug monitoring programs. Mitra with VAMS improves the end-user experience, streamlines sample collection processes, and enables the generation of reliable data.
Download these case studies to see how many leading organizations rely on Mitra with VAMS microsampling technology as the gold-standard in remote specimen collection.
|
|
Contact Us
Trajan Scientific Americas Inc.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Mitra® devices are intended as a specimen collector and for the storage and transport of blood. They are CE-IVD in the UK and EU, a Class 1 IVD in Australia, Brazil & China, Class B in South Africa, and registered with health agencies in Canada and Ukraine.
In the USA, Mitra devices are supplied as a Research-Use Only (RUO) product, to assist in method development, other research-related and non-diagnostic activities. Mitra has not been validated for use with any diagnostic testing. The suitability of Mitra for any analytical application must be evaluated and validated by the laboratory or research institute in a manner consistent with local regulatory requirements.
hemaPEN® is supplied for therapeutic or IVD use in Australia, New Zealand, UK, EU and USA only: ARTG number: 280007; CE mark, general IVD; US FDA number: D410490. Outside of the territories listed above, the hemaPEN is supplied for research use only (RUO) and not for therapeutic or diagnostic use.
Mitra®, VAMS® & hemaPEN® are registered trademarks owned by entities in the Trajan Group.
Copyright © 2022. All rights reserved.